- ICH GCP
- Registro de ensayos clínicos de EE. UU.
- Ensayo clínico NCT00045448
Combination Chemotherapy in Treating Patients With Advanced Solid Tumors
Single Center Open-Label Non-Comparative Phase I Dose Finding Study Of Weekly Flavopiridol In Combination With Weekly Docetaxel In Patients With Advanced Solid Tumors
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells.
PURPOSE: Phase I trial to study the effectiveness of combining flavopiridol with docetaxel in treating patients who have advanced solid tumors.
Descripción general del estudio
Estado
Intervención / Tratamiento
Descripción detallada
OBJECTIVES:
- Determine the maximum tolerated dose of flavopiridol when administered in combination with 2 different doses of docetaxel in patients with advanced solid tumors.
- Determine the clinical pharmacokinetics of this regimen in these patients.
- Determine, preliminarily, the therapeutic activity of this regimen in these patients.
OUTLINE: This is a dose-escalation study of flavopiridol.
Patients receive docetaxel IV over 30 minutes followed at least 4 hours later by flavopiridol IV over 1 hour on days 1, 8, and 15. Courses repeat every 4 weeks in the absence of disease progression or unacceptable toxicity.
Cohorts of 3-6 patients receive escalating doses of flavopiridol until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose preceding that at which at least 2 of 6 patients experience dose-limiting toxicity. Separate MTDs of flavopiridol are determined when flavopiridol is combined with 2 different doses of docetaxel. A total of 10 patients are treated at each flavopiridol MTD.
Patients are followed every 3 months for 1 year, every 6 months for 1 year, and then annually thereafter.
PROJECTED ACCRUAL: A total of 6-56 patients will be accrued for this study.
Tipo de estudio
Fase
- Fase 1
Contactos y Ubicaciones
Ubicaciones de estudio
-
-
New York
-
New York, New York, Estados Unidos, 10021
- Memorial Sloan-Kettering Cancer Center
-
-
Criterios de participación
Criterio de elegibilidad
Edades elegibles para estudiar
Acepta Voluntarios Saludables
Géneros elegibles para el estudio
Descripción
DISEASE CHARACTERISTICS:
- Histologically confirmed advanced solid tumor that is refractory to standard therapy or for which no standard therapy exists
- Measurable or evaluable disease
- No symptomatic or untreated CNS metastases or primary CNS neoplasm
PATIENT CHARACTERISTICS:
Age
- 18 and over
Performance status
- Karnofsky 70-100%
Life expectancy
- Not specified
Hematopoietic
- WBC at least 3,500/mm3
- Absolute neutrophil count at least 1,500/mm3
- Platelet count at least 100,000/mm3
- Hemoglobin at least 8 g/dL
Hepatic
- Bilirubin no greater than upper limit of normal (ULN)
- SGOT/SGPT no greater than 2.5 times ULN if alkaline phosphatase no greater than ULN OR
- Alkaline phosphatase no greater than 2.5 times ULN if SGOT/SGPT no greater than ULN
Renal
- Creatinine no greater than 1.5 mg/dL
Cardiovascular
- No history of cardiac arrhythmias
- No congestive heart failure
- No myocardial infarction within the past 6 months
Other
- No concurrent serious or uncontrolled infection
- No diabetes not adequately controlled with medication
- No peripheral neuropathy greater than grade 1
- No known allergy to docetaxel or other medications formulated in Polysorbate 80
- Not pregnant or nursing
- Negative pregnancy test
- Fertile patients must use effective contraception during and for 2 months after study
PRIOR CONCURRENT THERAPY:
Biologic therapy
- At least 4 weeks since prior immunotherapy
Chemotherapy
- At least 4 weeks since prior chemotherapy (6 weeks for nitrosoureas or mitomycin)
- Prior taxanes allowed
- No prior flavopiridol
Endocrine therapy
- At least 4 weeks since prior hormonal therapy
Radiotherapy
- At least 4 weeks since prior radiotherapy
Surgery
- Not specified
Other
- Recovered from prior therapy
- No prior enrollment in this study
Plan de estudios
¿Cómo está diseñado el estudio?
Detalles de diseño
- Propósito principal: Tratamiento
Colaboradores e Investigadores
Patrocinador
Fechas de registro del estudio
Fechas importantes del estudio
Inicio del estudio
Finalización primaria (Actual)
Finalización del estudio (Actual)
Fechas de registro del estudio
Enviado por primera vez
Primero enviado que cumplió con los criterios de control de calidad
Publicado por primera vez (Estimar)
Actualizaciones de registros de estudio
Última actualización publicada (Estimar)
Última actualización enviada que cumplió con los criterios de control de calidad
Última verificación
Más información
Términos relacionados con este estudio
Palabras clave
Términos MeSH relevantes adicionales
- Neoplasias
- Efectos fisiológicos de las drogas
- Mecanismos moleculares de acción farmacológica
- Inhibidores de enzimas
- Agentes antineoplásicos
- Moduladores de tubulina
- Agentes antimitóticos
- Moduladores de mitosis
- Sustancias de crecimiento
- Inhibidores del crecimiento
- Inhibidores de la proteína quinasa
- Docetaxel
- Alvocidib
Otros números de identificación del estudio
- AVENTIS-HMR1275A/1501
- MSKCC-02034
- NCI-G02-2106
- CDR0000256563 (Identificador de registro: PDQ (Physician Data Query))
Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .
Ensayos clínicos sobre docetaxel
-
Nereus Pharmaceuticals, Inc.TerminadoCáncerEstados Unidos, Australia, India, Chile, Brasil, Argentina
-
Optimal Health ResearchTerminadoCáncer de mama | Cáncer de pulmón | Cancer de prostataEstados Unidos
-
Tianjin Medical University Cancer Institute and...Reclutamiento
-
Jiangsu HengRui Medicine Co., Ltd.Shanghai Pulmonary Hospital, Shanghai, ChinaTerminadoCáncer de pulmón de células no pequeñas (CPCNP)Porcelana
-
National Cancer Center, KoreaSeoul National University Bundang Hospital; Gachon University Gil Medical Center y otros colaboradoresDesconocidoCáncer gástricoCorea, república de
-
Zhuhai Beihai Biotech Co., LtdTerminadoTumores Sólidos | Bioequivalencia | DocetaxelIndia
-
Arog Pharmaceuticals, Inc.RetiradoCarcinoma de pulmón de células no pequeñas
-
SanofiTerminadoNeoplasias PulmonaresFrancia, Países Bajos, España, Pavo, Bélgica, Finlandia, Italia, Reino Unido
-
SanofiTerminadoNeoplasias de Cabeza y CuelloFrancia
-
Fudan UniversityAún no reclutandoCáncer de pulmón de células no pequeñas avanzado